Mary Talley Bowden on mrna: what the evidence says · JRE #2335
SUBJECT: MRNA
Not a true/false call. Every claim is logged with its sources; read the exhibits below.
And we need the new administration to step up and do something because the next, they have 500 mRNA shots in the pipeline. 33 of those are self-amplifying,
What the evidence says 01 / RECORD
Published surveys of the mRNA clinical development landscape do not support figures of 500 mRNA shots or 33 self-amplifying candidates. A 2025 peer-reviewed review of therapeutic and self-amplifying RNA reports that only about six saRNA vaccine candidates have entered human clinical trials (COVAC1, ARCT-154, RBI-4000, LNP-nCOV saRNA-02, ARCT-021 and GEMCOVAC-OM), and that just one saRNA product, Arcturus's ARCT-154, has been approved anywhere. The pivotal ARCT-154 program, published in Nature Communications, describes that single saRNA COVID-19 vaccine rather than any large slate of self-amplifying shots. Broader tallies of all mRNA candidates (vaccines plus therapeutics) run in the low hundreds across cancer and infectious disease, most in early phases, well below a total of 500 self-amplifying-capable products, and the specific 500 and 33 figures trace to advocacy blog posts rather than a registry or regulatory source. The claim is exaggerated: the documented saRNA clinical pipeline is roughly six candidates, not 33.